Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
BMC Cardiovasc Disord. 2024 Mar 19;24(1):167. doi: 10.1186/s12872-024-03814-1.
Paclitaxel is a chemotherapeutic agent commonly used for ovarian, lung, breast carcinoma, and Kaposi's sarcoma. Its common side effects include hypersensitivity reaction, bone marrow suppression, and peripheral neuropathy. However, a rare and life-threatening side effect is paclitaxel-induced myocardial infarction.
A 71-year-old man with type 2 diabetes mellitus, hypertension, heavy smoking history, previous coronary artery disease with percutaneous coronary intervention (PCI) in left anterior descending artery (LAD), and non-small lung cancer presented with non-ST elevation myocardial infarction during infusion of paclitaxel infusion. Coronary angiogram showed de novo three vessel disease with 70% stenosis in ostial to distal left main artery (LM) and 80% in-stent re-stenosis in proximal to mid left anterior descending artery.
Physicians should be keeping this in mind when dealing with patients on paclitaxel, especially if they have previous risk factors for coronary artery disease.
紫杉醇是一种常用于卵巢癌、肺癌、乳腺癌和卡波西肉瘤的化疗药物。其常见的副作用包括过敏反应、骨髓抑制和周围神经病。然而，紫杉醇引起的心肌梗死是一种罕见且危及生命的副作用。
一名 71 岁男性，患有 2 型糖尿病、高血压、大量吸烟史、既往有经皮冠状动脉介入治疗（PCI）的前降支（LAD）冠状动脉疾病和非小细胞肺癌，在输注紫杉醇时发生非 ST 段抬高型心肌梗死。冠状动脉造影显示新出现的三支血管病变，左主干（LM）开口至远段 70%狭窄，前降支近段至中段 80%支架内再狭窄。
当处理接受紫杉醇治疗的患者时，医生应牢记这一点，特别是如果他们有以前的冠状动脉疾病风险因素。
